Table 4.
Results of the bivariate and multivariate Cox regression analysis of HIV patients receiving antiretroviral treatment, Jinka Hospital, South Omo, Ethiopia in 2016 (n=350)
| Characteristics | Bivariate HR (95% CI) | p-value | Multivariate aHR (95% CI) | p-value |
|---|---|---|---|---|
| Disclosure status | ||||
| Yes | 1.00 (reference) | 1.00 (reference) | ||
| No | 3.49 (1.48, 8.22) | 0.004 | 5.82 (1.91, 17.72) | 0.02 |
| Past TB treatment | ||||
| Yes | 4.20 (1.96, 8.99) | <0.001 | 1.82 (1.41,3.51) | 0.04 |
| No | 1.00 (reference) | 1.00 (reference) | ||
| Functional status | ||||
| Working | 1.00 (reference) | 1.00 (reference) | ||
| Ambulatory | 5.98 (2.64, 13.54) | < 0.001 | 2.97 (1.20, 8.86) | 0.05 |
| Bedridden | 20.64 (7.65, 55.68) | < 0.001 | 4.67 (1.30, 17.27) | 0.02 |
| WHO staging | ||||
| I and II | 1.00 (reference) | 1.00 (reference) | ||
| III and IV | 2.41 (1.50, 5.52) | 0.04 | 3.25 (1.98, 10.7) | 0.05 |
| Baseline CD4 count (cells/μL) | ||||
| 0-350 | 4.31 (1.34-17.97) | 0.05 | 3.38 (0.71, 16.02) | 0.33 |
| 351-1,200 | 1.00 (reference) | 1.00 (reference) | ||
| Substance use | ||||
| Yes | 4.57 (1.87, 11.21) | 0.001 | 3.72 (1.39, 9.97) | 0.009 |
| No | 1.00 (reference) | 1.00 (reference) | ||
| Initial regimens | ||||
| 1a=D4T-3TC-NVP | 3.47 (1.24, 9.79) | 0.02 | 1.66 (0.45, 6.14) | 0.45 |
| 1b=D4T-3TC-EFV | 2.95 (0.64, 13.71) | 0.16 | 0.54 (0.07, 4.42) | 0.57 |
| 1c=AZT-3TC-NVP | 0.52 (0.07, 3.98) | 0.53 | 0.39 (0.05, 3.28) | 0.38 |
| 1d=AZT-3TC-EFV | 0.00 (0.00, 0.00) | 0.98 | 0.00 (0.00, 0.00) | 0.98 |
| 1e=TDF-3TC-EFV | 0.51 (0.24, 1.10) | 0.08 | 0.20 (0.07, 0.53) | 0.001 |
| 1f=TDF+3TC+NVP | 1.00 (reference) | 1.00 (reference) |
HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; TB, tuberculosis; WHO, World Health Organization; AZT, zidovudine; 3TC, lamivudine; D4T, stavudine; NVP, nevirapine; EFV, efavirenz.